FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897208096> ?p ?o ?g. }

• W2897208096 endingPage "S315" @default.
• W2897208096 startingPage "S315" @default.
• W2897208096 abstract "Anlotinib is an effective multi-targeted receptor tyrosin kinase inhibitor (TKI) for refractory advanced Non-Small Cell Lung Cancer (NSCLC) therapy at 3rd line. ALTER-0303 clinical trial has been revealed that Anlotinib significantly prolongs progression free survival (PFS; Anlotinib: 5.37 months vs Placebo: 1.40 months) and overall survival (OS; Anlotinib: 9.63 months vs Placebo: 6.30 months) with the objective response rate (ORR) of 9.18% and the disease control rate (DCR) of 80.95%. Here, we sought to understand the gene mutation determinants for clinical response to Anlotinib via next generation sequencing (NGS) upon cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) at baseline. Totally 437 advanced NSCLC patients enrolled in ALTER-0303 study, and 294 patients received Anlotinib therapy. Of the 294 patients, 80 patients were analyzed in the present study. Capture-based targeted ultradeep sequencing was performed to obtain germline and somatic mutations in cfDNA and ctDNA. Response analyses upon discovery cohort (n = 62) and validation cohort (n = 80) were performed by use of germline and somatic (G+S) mutation burden, somatic mutation burden, nonsynonymous mutation burden, and unfavorable mutation score (UMS), respectively. Based on the above independent biomarkers and their subtype factors, tumor mutation index (TMI) was developed, and then used for response analysis. Our data indicated that the patients harbouring less mutations are better response to Anlotinib therapy (G+S muatation burden, cutoff = 4000, Median PFS: 210 days vs 127 days, p = 0.0056; somatic mutation burden, cutoff = 800, Median PFS: 210 days vs 130 days; p = 0.0052; nonsynonymous mutation burden, cutoff = 50, Median PFS: 209 days vs 130 days; p = 0.0155; UMS, cutoff = 1, Median PFS: 210 days vs 131 days; p = 0.0016). TMI is an effective biomarker for Anlotinib responsive stratification (Median PFS: 210 days vs 126 days; p= 0.0008; AUC = 0.76, 95% CI: 0.62 to 0.89) upon discovery cohort and validation cohort (Median PFS: 210 days vs 127 days; p = 0.0006). Lastly, integrative analysis of TMI and IDH1 mutation suggested a more promising result for Anlotinib responsive stratification upon validation cohort (Median PFS: 244 days vs 87 days; p < 0.0001; AUC = 0.90, 95% CI: 0.82 to 0.97). This study provide a biomarker of TMI to stratify Anlotinib underlying responders, that may improve clinical outcome for Anlotinib therapy on refractory advanced NSCLC patients at 3rd line. Clinical trial information: NCT02388919." @default.
• W2897208096 created "2018-10-26" @default.
• W2897208096 creator A5007453350 @default.
• W2897208096 creator A5008750923 @default.
• W2897208096 creator A5021139793 @default.
• W2897208096 creator A5033872286 @default.
• W2897208096 creator A5047481403 @default.
• W2897208096 creator A5048704005 @default.
• W2897208096 creator A5080634694 @default.
• W2897208096 creator A5087244383 @default.
• W2897208096 date "2018-10-01" @default.
• W2897208096 modified "2023-09-30" @default.
• W2897208096 title "JCSE01.19 ALTER-0303 Study: Tumor Mutation Index (TMI) For Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line" @default.
• W2897208096 doi "https://doi.org/10.1016/j.jtho.2018.08.225" @default.
• W2897208096 hasPublicationYear "2018" @default.
• W2897208096 type Work @default.
• W2897208096 sameAs 2897208096 @default.
• W2897208096 citedByCount "0" @default.
• W2897208096 crossrefType "journal-article" @default.
• W2897208096 hasAuthorship W2897208096A5007453350 @default.
• W2897208096 hasAuthorship W2897208096A5008750923 @default.
• W2897208096 hasAuthorship W2897208096A5021139793 @default.
• W2897208096 hasAuthorship W2897208096A5033872286 @default.
• W2897208096 hasAuthorship W2897208096A5047481403 @default.
• W2897208096 hasAuthorship W2897208096A5048704005 @default.
• W2897208096 hasAuthorship W2897208096A5080634694 @default.
• W2897208096 hasAuthorship W2897208096A5087244383 @default.
• W2897208096 hasBestOaLocation W28972080961 @default.
• W2897208096 hasConcept C104317684 @default.
• W2897208096 hasConcept C109825262 @default.
• W2897208096 hasConcept C121332964 @default.
• W2897208096 hasConcept C121608353 @default.
• W2897208096 hasConcept C126322002 @default.
• W2897208096 hasConcept C134305767 @default.
• W2897208096 hasConcept C13514818 @default.
• W2897208096 hasConcept C142424586 @default.
• W2897208096 hasConcept C143998085 @default.
• W2897208096 hasConcept C2781230642 @default.
• W2897208096 hasConcept C501734568 @default.
• W2897208096 hasConcept C54355233 @default.
• W2897208096 hasConcept C71924100 @default.
• W2897208096 hasConcept C72563966 @default.
• W2897208096 hasConcept C86803240 @default.
• W2897208096 hasConcept C87355193 @default.
• W2897208096 hasConceptScore W2897208096C104317684 @default.
• W2897208096 hasConceptScore W2897208096C109825262 @default.
• W2897208096 hasConceptScore W2897208096C121332964 @default.
• W2897208096 hasConceptScore W2897208096C121608353 @default.
• W2897208096 hasConceptScore W2897208096C126322002 @default.
• W2897208096 hasConceptScore W2897208096C134305767 @default.
• W2897208096 hasConceptScore W2897208096C13514818 @default.
• W2897208096 hasConceptScore W2897208096C142424586 @default.
• W2897208096 hasConceptScore W2897208096C143998085 @default.
• W2897208096 hasConceptScore W2897208096C2781230642 @default.
• W2897208096 hasConceptScore W2897208096C501734568 @default.
• W2897208096 hasConceptScore W2897208096C54355233 @default.
• W2897208096 hasConceptScore W2897208096C71924100 @default.
• W2897208096 hasConceptScore W2897208096C72563966 @default.
• W2897208096 hasConceptScore W2897208096C86803240 @default.
• W2897208096 hasConceptScore W2897208096C87355193 @default.
• W2897208096 hasIssue "10" @default.
• W2897208096 hasLocation W28972080961 @default.
• W2897208096 hasOpenAccess W2897208096 @default.
• W2897208096 hasPrimaryLocation W28972080961 @default.
• W2897208096 hasRelatedWork W2071881731 @default.
• W2897208096 hasRelatedWork W2076264678 @default.
• W2897208096 hasRelatedWork W2093376340 @default.
• W2897208096 hasRelatedWork W2122019564 @default.
• W2897208096 hasRelatedWork W2162571700 @default.
• W2897208096 hasRelatedWork W2613868166 @default.
• W2897208096 hasRelatedWork W2762413087 @default.
• W2897208096 hasRelatedWork W3109878606 @default.
• W2897208096 hasRelatedWork W4225922992 @default.
• W2897208096 hasRelatedWork W4296737991 @default.
• W2897208096 hasVolume "13" @default.
• W2897208096 isParatext "false" @default.
• W2897208096 isRetracted "false" @default.
• W2897208096 magId "2897208096" @default.
• W2897208096 workType "article" @default.